Effect of Bailing capsule combined with azithromycin on mycoplasma pneumonia in children and the levels of serunrsPD-landCYTL1 Liang Wenting, Wu Xiaohong , Yan Haifeng, Huo Kaiming. Department of Pediatrics , the Second Affiliated Hospital of Hainan Medical College ,Hainan Province , Haikou 570311 , ChinaCorresponding author: Huo Kaiming, E-mail: panda686@ yeah. netFunding program : Health Industry Scientific Research Project of Hainan Province( 20A200095)

Abstract：

Objective To observe the therapeutic effect of Bailing capsule combined with azithromycin on mycoplasma pneumonia in children and its influence on the levels of serum soluble programmed death receptor 1(sPD-1) and cytokine like protein 1(CYTL1). Methods From March 2018 to September 2021, 140 children with mycoplasma pneumonia diagnosed and treated in Pediatric Division II of the Second Affiliated Hospital of Hainan Medical College were selected and divided into the control group and the observation group by random number table method, with 70 cases in each group. The control group was treated with azithromycin, and the observation group was treated with Bailing capsule on the basis of the control group. The total effective rate, symptom improvement time, pulmonary function indexes(FEV₁, FVC, FEV₁/FVC), blood gas analysis(PaO₂, PaCO₂, pH, SaO₂), inflammatory factors(CRP, IL-6, IL-10, TNF-α) before and after treatment were compared between the two groups-α, immune function indicators [CD4⁺, CD4⁺/CD8⁺, CD3⁺, immunoglobulin G(IgG)], serum sPD-1, CYTL1 levels, and adverse reactions. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant(82.86% vs.67.14%, χ²=4.809,P=0.028). The cough relief time, blood picture recovery time, antipyretic time and rale disappearance time in the observation group were significantly lower than those in the control group(t=23.253, 14.382, 33.859, 14.960, P<0.001). After 2 weeks of treatment, the levels of FEV₁ and FEV₁/FVC in the observation group were significantly higher than those in the control group(t=17.305, 8.743, P<0.001). PaO₂, pH, SaO₂ levels were significantly higher than those in the control group, and PaCO₂ levels were significantly lower than those in the control group(t=10.717, 5.435, 7.513, 6.426, all P<0.001). Serum CRP, IL-6, IL-10, TNF-α The level was significantly lower than that of the control group(t=24.031, 7.203, 8.499, 7.743, P<0.001). The levels of CD4⁺, CD4⁺/CD8⁺, CD3⁺ and IgG in the control group were higher than those in the control group(t=7.130, 4.830, 7.298, 5.698, P<0.001). The level of serum sPD-1 was significantly lower than that of the control group, and the level of CYTL1 was significantly higher than that of the control group(t=10.292, 7.787, P<0.001). there="" was="" no="" significant="" difference="" in="" the="" incidence="" of="" adverse="" reactions="" between="" two="" p="">0.05). Conclusion Bailing capsule combined with azithromycin can significantly improve the clinical efficacy of children with mycoplasma pneumonia, shorten the time for symptom improvement, enhance lung function, improve blood gas analysis indicators, reduce the level of inflammatory factors, improve immune function, reduce the level of serum sPD-1, and increase the level of CYTL1, with good safety.

Mycoplasma pneumonia;                    Bailing capsule;                    Azithromycin;                    Soluble programmed death receptor 1;                    Cytokine like protein 1;                    Children;